Last spring, a group of affluent women gathered for an intimate dinner in Austin, sipping pregnancy-safe mocktails while listening to Noor Siddiqui, founder of the fertility tech start-up Orchid Health.
Siddiqui shared her ambitious vision of using advanced genome sequencing and data algorithms to screen embryos for thousands of potential illnesses, aiming to give future children a healthier start.
Orchid Health, based in San Francisco, is pioneering comprehensive embryo screening that analyzes the entire genome — all 3 billion base pairs — from just a few cells.
This technology screens for more than 1,200 rare genetic disorders and calculates polygenic risk scores to assess a child’s likelihood of developing complex diseases such as cancer, Alzheimer’s, bipolar disorder, schizophrenia, and obesity.
While currently affordable mainly to wealthy tech insiders, Orchid’s services could soon influence mainstream reproductive choices, raising ethical and social questions about selecting embryos based on genetic risk.
Siddiqui envisions a future where embryo screening becomes routine, potentially replacing natural conception for many parents focused on maximizing health outcomes.
“People don’t want to take chances when it comes to their children’s health,” Siddiqui told The Washington Post. For her and her clients, paying $2,500 per embryo screening on top of IVF costs is an investment in reducing the risk of disease.
This shift towards data-driven, personalized reproductive health could mark a significant advance in preventing hereditary diseases before birth. As embryo screening technology becomes more accessible, it may transform how families plan for healthier futures.
Related topics:
